Medication info
Amantine Tablet 20mg (Memantine Hydrochloride)

Amantine Tablet 20mg (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›20mg / 1 tablet
Manufacturer / importer
Aprogen Biologics Co., Ltd.
Appearance
Pink, oval, film-coated tablet
Packaging
Bottle packaging - 30 tablets/bottle [Bottle: HDPE, Cap: LDPE], Bottle packaging - 100 tablets/bottle [Bottle: HDPE, Cap: LDPE]
Approval status
Active

MFDS item code 202401047 · Approved 2024.04.30 · Insurance code 645210920

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
Administer this medicine orally once daily at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1–7) Administer 5mg once daily for 7 days. Week 2 (days 8–14) Administer 10mg once daily for 7 days. Week 3 (days 15–21) Administer 15mg once daily for 7 days. From week 4 onward Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. Older adults Based on clinical data, the recommended dose for patients aged 65 years and older is 20mg once daily. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-escalation regimen. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), reduce the daily dose to 10mg. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Because there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Ingredients

Manufacturer
Aprogen Biologics Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

View approved original text

This medication is used to alleviate the symptoms of patients with moderate to severe Alzheimer's disease. It helps improve cognitive decline, including memory loss, allowing patients to maintain their daily living abilities. It also contributes to stabilizing behavioral and psychiatric symptoms, thus improving the quality of life. Overall, it is effective for the treatment of severe Alzheimer's disease.

How to take

Adult dose

Administer this medicine orally once daily at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1–7) Administer 5mg once daily for 7 days. Week 2 (days 8–14) Administer 10mg once daily for 7 days. Week 3 (days 15–21) Administer 15mg once daily for 7 days. From week 4 onward Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. Older adults Based on clinical data, the recommended dose for patients aged 65 years and older is 20mg once daily. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-escalation regimen. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), reduce the daily dose to 10mg. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Because there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Precautions

This medication should not be used in patients with hypersensitivity to its components or in patients with severe liver or kidney impairments. It should be used cautiously in patients with epilepsy or a history of seizures, as well as in patients with a predisposition to seizures. Using NMDA antagonists such as amantadine, ketamine, or dextromethorphan together may increase central nervous system side effects, so they should not be combined. Careful monitoring is advised in situations where urine pH may increase, for example, due to dietary changes or certain urinary tract infections. Caution is warranted in patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension, as the safety of this drug has not been sufficiently established in these populations. During the use of this medication, side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur; if symptoms are severe, consultation with a healthcare professional is advised. This medication may interact with other drugs, so special caution is needed when taken with levodopa, dopamine agonists, anticholinergics, barbiturates, antipsychotics, or skeletal muscle relaxants. Women who are pregnant or may become pregnant should consult their physician before taking this medication, and nursing mothers are recommended to stop breastfeeding while taking this medication. It is advisable to avoid using this medication in children or adolescents under 18 years of age, as its safety and efficacy have not been established. In cases of overdose, symptoms such as confusion, drowsiness, dizziness, hallucinations, seizures, and vomiting may occur, so immediate medical attention is required. This medication can affect the central nervous system, so caution is necessary when driving or operating machinery. Store out of reach of children and do not transfer the medication to other containers to ensure safety and maintain quality.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • confusion
  • hallucination
  • psychiatric reaction
Show 19 more
  • balance disorder
  • gait abnormality
  • seizure
  • heart failure
  • venous thrombosis/thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver function test results
  • hepatitis
  • fatigue
  • abnormal confusion
  • sleepiness
  • anxiety
  • aggression
  • gait disturbance
  • visual disturbance
  • delirium
  • unconsciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, ideally at room temperature between 1 and 30 degrees Celsius. Storing it this way can help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pink, oval, film-coated tablet

Package unit

Bottle packaging - 30 tablets/bottle [Bottle: HDPE, Cap: LDPE], Bottle packaging - 100 tablets/bottle [Bottle: HDPE, Cap: LDPE]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.